|
|
| Line 1: |
Line 1: |
| | | #REDIRECT [[Frovatriptan#Clinical Studies]] |
| | |
| __NOTOC__
| |
| {{Frovatriptan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Clinical Studies==
| |
| | |
| The efficacy of FROVA in the acute treatment of [[migraine]] headaches was demonstrated in four randomized, double-blind, placebo-controlled, short-term outpatient trials. In these trials, patients received doses of frovatriptan from 0.5 mg to 40 mg. In these controlled short-term trials, patients were predominately female (88%) and Caucasian (94%) with a mean age of 42 years (range 18 - 69). Patients were instructed to treat a moderate to severe headache. headache response, defined as a reduction in headache severity from moderate or severe pain to mild or no pain, was assessed for up to 24 hours after dosing. The associated symptoms nausea, vomiting, [[photophobia]] and [[phonophobia]] were also assessed. Maintenance of response was assessed for up to 24 hours post dose. In two of the trials a second dose of FROVA was provided after the initial treatment, to treat recurrence of the headache within 24 hours. Other medication, excluding other 5-HT1 agonists and ergotamine containing compounds, was permitted from 2 hours after the first dose of FROVA. The frequency and time to use of additional medications were also recorded.
| |
| | |
| In all four placebo-controlled trials, the percentage of patients achieving a headache response 2 hours after treatment was significantly greater for those taking FROVA 2.5 mg compared to those taking placebo (Table 2).
| |
| | |
| Lower doses of frovatriptan (1 mg or 0.5 mg) were not effective at 2 hours. Higher doses (5 mg to 40 mg) of frovatriptan showed no added benefit over 2.5 mg but did cause a greater incidence of adverse events.
| |
| | |
| {|
| |
| |-
| |
| |[[File:Frovatriptan03.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| {|
| |
| |-
| |
| |[[File:Frovatriptan04.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| Figure 1 shows a Kaplan-Meier plot of the probability over time of obtaining headache response (no or mild pain) following treatment with FROVA 2.5 mg or placebo. The probabilities displayed are based on pooled data from the four placebo-controlled trials described in Table 2. Patients who did not achieve a response were censored at 24 hours.
| |
| | |
| In patients with [[migraine]]-associated nausea, [[photophobia]] and [[phonophobia]] at baseline there was a decreased incidence of these symptoms in FROVA treated patients compared to placebo.
| |
| | |
| The estimated probability of patients taking a second dose or other medication for their [[migraine]] over the 24 hours following the initial dose of study treatment is summarized in Figure 2.
| |
| | |
| Figure 2
| |
| Estimated Probability of Patients Taking a Second Dose or Other Medication for [[migraine]]
| |
| Over the 24 Hours Following the Initial Dose of Study Treatment
| |
| | |
| {|
| |
| |-
| |
| |[[File:Frovatriptan05.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| Figure 2 is a Kaplan-Meier plot showing the probability of patients taking a second dose or other medication for [[migraine]] over the 24 hours following the initial dose of study medication based on the data from the four placebo-controlled trials described in Table 2. The plot includes those patients who had a response to the initial dose and those who did not. The protocols did not permit remedication within 2 hours of the initial dose.
| |
| | |
| Efficacy was unaffected by a history of aura; gender; age, or concomitant medications commonly used by [[migraine]] patients.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = FROVA (FROVATRIPTAN SUCCINATE) TABLET, FILM COATED [ENDO PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0703630-9ce8-4259-841e-71fd2019fa66 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Antimigraine drugs]]
| |
| [[Category:Triptans]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |